Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin vs Idarubicin in Elderly AML (ALFA1401)
NCT02473146Phase 3Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Nov 2015
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Centre Hospitalier de Versailles. Started Nov 2015; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02473146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473146.